Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia

Pediatric Hematology and Oncology

Volumn 31, Issue 4, 2014, Pages 311-317

  Petersen Jr , William C ^a   Clark, Dana ^b   Senn, Stacy L ^b   Cash, W Thomas ^b   Gillespie, Scott E ^c   McCracken, Courtney E ^c   Keller, Frank G ^b   Lew, Glen ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALL; Allergy; Intramuscular; Intravenous; Pegaspargase

Indexed keywords

ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; ASPARAGINASE; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CHILD; CHILD HOSPITALIZATION; CHILDHOOD LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; ADOLESCENT; INFANT; INTRANASAL DRUG ADMINISTRATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFANT; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 84899107481     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.876134     Document Type: Article

References (17)

1. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010;10(5):833-839.
2. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J ClinOncol. 2005;23(28):7161-7167.
3. Abshire TC, Pollock BH, Billett AL, et al.Weekly polyethylene glycol conjugated L-asparaginase comparedwith biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96(5):1709-1715.
4. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665-1679.
5. Haskell CM, Canellos GP. l-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol. 1969;18(10):2578-2580.
6. Petersen RG,Handschumacher RE,Mitchell MS. Immunological responses to L-asparaginase. J Clin Invest. 1971;50(5):1080-1090.
7. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554-563.
8. Kamisaki Y,WadaH, Yagura T, et al. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther. 1981;216(2):410-414.
9. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children?s Cancer Group study. Blood. 2002;99(6):1986-1994.
10. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744-2750.
11. Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children?s Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24(3):175-181.
12. Silverman LB, Gelber RD,Dalton VK, et al. Improved outcome for childrenwith acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218.
13. Kurtzberg J, Asselin B, Bernstein M, et al. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bonemarrow relapse: a Children?s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610-616.
14. Nesbit M, KaronM, Chard R, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1(1):9-13.
15. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351-1353.
16. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer. 2012;59(3):436-439.
17. August KJ, Miller WP, Dalton A, Shinnick S, et al. Comparison of hypersensitivity reactions to PEGasparaginase in children after intravenous and intramuscular administration. J Pediatr Hematol Oncol. 2013;35(7):e283-e286.